Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (3256)	6/8/1999 11:22:00 AM
From: quidditch	Read Replies (2) \| Respond to of 10280

I feel (y)our pain, Bruce. How does this number compare to some of the thread's assumptions underlying unofficial projections? David, any shock for you, or within bounds? As a benchmark for this footprint--i.e., licensing the ICE to the pharma holding patents and marketing rights of the racemic version--five percent seems low. What factors might account for this negotiation on Zyrtec? More questions than answers, today. Peter, thnks for your thoughts. All it takes is bucks to demonstrate the superiority to the racemic version, assuming such superiority exists. And this goes back to my oft-repeated concern (tiresome to the thread, I know) about burn. I guess the good news from IJF's synopsis of the conf' was that SGP intends to file NDA for desloratidine in y2k, if I recall. Regards. Steven

To: BMcV who wrote (3256)	6/8/1999 11:31:00 AM
From: quidditch	Read Replies (1) \| Respond to of 10280

OT Novartis As an OT aside, a neighbor of mine, in his 60's, was diagnosed as having leukemia a couple of years ago. He tried many treatment approaches for the disease, including one of the better known mca (maybe a Genetech product, interferon?), whose name escapes me just now. After false starts and hopes, he opted to participate in a Phase I trial for a Novartis drug. To his delight, and that of everyone in his patient pool in Texas (according to the physicians administering the trial, which is now completed with respect to that pool), each has responded with close to normal blood counts, they continue taking the drug with no apparent severe (or other, my neighbor mentioned none) side effects. FWIW Regards. Liacos_samui